Myxoid Leiomyosarcoma|OMICS International|Primary Health Care: Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Recommended Webinars & Conferences

Myxoid Leiomyosarcoma

Uterine sarcomas account for 3% of uterine cancers. Uterine sarcomas comprise leiomyosarcoma, endometrial stromal sarcoma, adenosarcoma, undifferentiated endometrial sarcoma, and their variants. The rarity of these tumors has prevented the performance of large epidemiological studies to identify risk factors. Data regarding parity, onset of menarche, or age at menopause as risk factors are inconclusive. Myxoid leiomyosarcoma (MLMSs) is an uncommon tumor, in most cases recognized only after surgery. When MLMSs is associated with multiple myomata, the gross appearance of the malignant mass differs from others for a soft, necrotic and gelatinous aspect. In the past, the presence of 10 or more mitoses per 10 high-power fields (HPFs) was considered key to establish the diagnosis of leiomyosarcoma. Even though mitotic index is an important feature in the assessment of malignancy, several studies based on large series of uterine smooth muscle tumors (U-SMTs) have shown that mitotic activity alone is not predictive of poor outcome in these tumors. Uterine Myxoid Leiomyosarcoma Associated with Multiple Myomas in a Fertile Woman: A Case Report Vito Leanza
  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger

Last date updated on June, 2021